Last reviewed · How we verify
Hospira, now a wholly owned subsidiary of Pfizer — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
2 Phase 2
5 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| DA-9501 | DA-9501 | phase 3 | Herbal extract / Hepatoprotective agent | Hepatology / Gastroenterology |
Therapeutic area mix
- Oncology · 2
- Hepatology / Gastroenterology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Hoffmann-La Roche · 1 shared drug class
- Jiangsu Hansoh Pharmaceutical Co., Ltd. · 1 shared drug class
- Life Extension Foundation Inc. · 1 shared drug class
- Remedor Biomed Ltd · 1 shared drug class
- Seoul National University Hospital · 1 shared drug class
- University Hospital, Brest · 1 shared drug class
- VA Office of Research and Development · 1 shared drug class
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Hospira, now a wholly owned subsidiary of Pfizer:
- Hospira, now a wholly owned subsidiary of Pfizer pipeline updates — RSS
- Hospira, now a wholly owned subsidiary of Pfizer pipeline updates — Atom
- Hospira, now a wholly owned subsidiary of Pfizer pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Hospira, now a wholly owned subsidiary of Pfizer — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hospira-now-a-wholly-owned-subsidiary-of-pfizer. Accessed 2026-05-17.